Paper Details

  1. Home
  2. Paper Details

Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.

Author: , LinazasoroGurutz

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Overnight switching from pergolide, ropinirole, and pramipexole to cabergoline was safe and showed clinical improvement.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Cabergoline is an ergotic dopamine agonist with D2 receptor activity and a very long half-life. This pharmacological profile may result in clinically different effects. Small clinical trials indicate that overnight switching from 1 agonist to another can be performed safely. OBJECTIVE: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18303487

データ提供：米国国立医学図書館（NLM）

Conversion from Dopamine Agonists to Cabergoline in Parkinson's Disease

Parkinson's disease (PD) is a chronic neurological disorder. This study evaluated the safety and efficacy of switching patients with advanced PD from dopamine agonists to cabergoline, a long-acting dopamine agonist, in an overnight schedule.

Safe and Effective Conversion to Cabergoline

The study found that switching from other dopamine agonists to cabergoline overnight was safe and well-tolerated, with a significant improvement in patients' motor function and quality of life. While some patients experienced side effects, the majority of patients benefited from the switch.

A Potential Treatment Option for Advanced PD

This research highlights the potential of cabergoline as a treatment option for advanced PD. Its long half-life may offer advantages in managing motor fluctuations and improving quality of life for patients with PD.

Dr. Camel's Conclusion

This study offers a promising avenue for managing advanced PD. It's like discovering a new oasis in the desert of Parkinson's research, offering hope for better management of this challenging condition. The results suggest that cabergoline could be a valuable tool in our arsenal for treating PD, leading to improved outcomes for patients.

Date :
  1. Date Completed 2008-03-11
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18303487

DOI: Digital Object Identifier

00002826-200801000-00003

Related Literature

Article Analysis
・Side Effects of cabergoline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.